Report Highlights

South Korea's Role in the Global Ophthalmic Viscoelastic Devices Supply Chain

South Korea occupies a net-importer position in the global OVD supply chain, relying on multinational manufacturers based in the United States, Switzerland, and Japan for the majority of its clinical supply. Alcon (USA) and Johnson & Johnson Vision (USA) together account for an estimated 60–65% of South Korean OVD procurement by value, with product manufactured at facilities in Fort Worth, Texas and Groningen, Netherlands before entering Korea through Incheon International Airport's pharmaceutical cold logistics corridor. Carl Zeiss Meditec and Bausch + Lomb supply the remaining premium tier, while Hoya Corporation serves as the primary Japanese-origin supplier through its Korean subsidiary, capitalizing on geographic proximity and established ophthalmic channel relationships built through IOL co-distribution agreements.

South Korea's domestic OVD manufacturing base remains underdeveloped relative to its broader medical device manufacturing capability. Korean firms such as Taejin Medical and Biovisio have attempted to develop hyaluronic acid-based OVD formulations, but none has achieved full MFDS approval for intraocular use at scale as of 2024. This gap means South Korea functions as a high-value consumption market rather than a processing or re-export hub. The country's significance in the global supply chain is therefore demand-side: its high per-capita cataract surgical rate — among the highest in the OECD — and concentrated hospital procurement system make it a strategically important market for multinational OVD suppliers benchmarking Asia-Pacific pricing and clinical adoption patterns.

Growth Drivers for South Korea's Ophthalmic Viscoelastic Devices Trade and Production

South Korea's rapidly aging population is the primary structural driver of OVD import volume growth. The country's 65-plus cohort is projected to reach 20% of total population by 2025–2026, generating a sustained increase in age-related cataract incidence. The National Health Insurance Service (NHIS) covers standard phacoemulsification procedures, directly stimulating surgical volumes at contracted hospitals. Korea performed an estimated 700,000-plus cataract surgeries annually as of 2023, placing it among the top five markets globally on a per-capita basis. Each procedure consumes one to two OVD units depending on surgical technique, creating predictable and growing import demand that multinational suppliers are actively working to lock in through multi-year hospital supply agreements.

Two additional drivers are reshaping the OVD trade profile beyond pure volume growth. First, the widespread adoption of micro-incision cataract surgery (MICS) and femtosecond laser-assisted cataract surgery (FLACS) at major academic medical centers — including Asan Medical Center, Samsung Medical Center, and Seoul National University Hospital — is accelerating demand for premium combination OVDs that offer superior retention and dispersive protection. These products carry 30–50% price premiums over standard cohesive OVDs, lifting average selling prices and total import value faster than unit volume alone. Second, South Korea's growing medical tourism industry in ophthalmology, particularly attracting patients from China, Vietnam, and the Middle East, is expanding the surgical base beyond domestic demographics and creating demand for differentiated, internationally recognized OVD brands that foreign patients specifically request by name.

Supply Chain Risks and Trade Barriers

The dominant supply chain risk for OVDs in South Korea is single-source import dependency on a small number of multinational manufacturers. With no domestic production at scale, any disruption to Alcon or Johnson & Johnson Vision's European manufacturing output — whether from regulatory action, logistics bottlenecks, or geopolitical disruption to air freight through Middle Eastern hubs — translates directly into Korean hospital stockouts. South Korea's average OVD inventory held by hospital pharmacies is estimated at 30–45 days, well below the 90-day buffer recommended for critical surgical consumables. The Incheon cold chain corridor, while highly efficient, is vulnerable to congestion during peak import periods when pharmaceutical and medical device consignments compete for temperature-controlled handling capacity.

Trade barrier risk centers on the MFDS (Ministry of Food and Drug Safety) regulatory pathway, which requires full Class III medical device registration for OVDs — a process that typically requires 18–24 months and substantial clinical data submission. Import tariffs on ophthalmic medical devices currently sit at 6.5% under the base MFN rate, though products from the United States benefit from a 0% tariff under the KORUS FTA, creating a structural cost advantage for American-origin OVDs over European and Japanese competitors. Currency volatility in the Korean won against the US dollar introduces periodic pricing pressure that can disrupt hospital procurement cycles, as OVD contracts are often dollar-denominated while hospital budgets are set in won on an annual basis.

Trade and Investment Opportunities in South Korea's Ophthalmic Viscoelastic Devices Market

The most immediate trade opportunity lies in penetrating South Korea's secondary and tertiary hospital segment, which remains underserved by premium OVD suppliers focused on the top-20 academic centers. South Korea has over 300 ophthalmology-specialized clinics and secondary hospitals performing cataract surgeries, many of which currently use generic or lower-tier OVD products due to limited distributor engagement. International OVD manufacturers that establish dedicated ophthalmic distribution partnerships — rather than relying on general medical device wholesalers — can capture meaningful volume from this underpenetrated segment. Strategic co-distribution with Korean IOL manufacturers such as Rayner Korea or local ophthalmic equipment suppliers represents an efficient route to this channel without building independent sales infrastructure from zero.

On the investment side, South Korea presents a viable location for OVD formulation and packaging operations targeting the broader Asia-Pacific export market. South Korea's established pharmaceutical GMP infrastructure, skilled biochemical workforce, and proximity to large-volume markets in China, Japan, and Southeast Asia make it a credible regional manufacturing hub for hyaluronic acid-based OVD products. A foreign direct investment play — establishing a joint venture with a Korean pharmaceutical manufacturer holding existing MFDS facility registration — would allow an international OVD company to produce regionally, access RCEP trade benefits for export to ASEAN markets, and qualify for South Korean government bio-health industry incentives available under the K-BIO strategy, which designates ophthalmic medical devices as a priority export category through 2030.

Market at a Glance

Leading Market Participants

• Alcon Inc.
• Johnson & Johnson Vision
• Carl Zeiss Meditec AG
• Bausch + Lomb
• Hoya Corporation
• Rayner Surgical Group
• Beaver-Visitec International
• Biovisio Co., Ltd.
• Taejin Medical
• Hanmi Pharmaceutical

Regulatory and Trade Policy Environment

OVDs in South Korea are regulated as Class III medical devices under the Medical Device Act administered by the Ministry of Food and Drug Safety (MFDS). Foreign manufacturers must obtain a Korean Importing Business License and submit a full technical dossier — including biocompatibility, sterility, and clinical performance data — for device registration prior to any commercial sale. The MFDS harmonizes substantially with ISO 10993 standards for biocompatibility and follows IMDRF guidelines, which reduces but does not eliminate redundant testing requirements for manufacturers already holding CE Mark or FDA 510(k) clearance. Registration fees, local representative requirements, and mandatory post-market surveillance reporting create meaningful compliance overhead that disproportionately burdens smaller international entrants relative to established multinationals with Korean regulatory affairs teams already in place.

Trade policy creates a tiered competitive landscape. Under the KORUS FTA (in force since 2012), US-manufactured OVDs enter South Korea at 0% tariff, giving Alcon and Johnson & Johnson Vision a structural landed-cost advantage over European competitors subject to the 6.5% MFN rate. The EU-Korea FTA has progressively reduced this gap — EU medical device tariffs are currently near zero under the agreement's staged reductions — but administrative origin documentation requirements still generate periodic delays. South Korea's participation in RCEP creates additional complexity for Japanese suppliers such as Hoya, who benefit from preferential RCEP rates but must comply with regional content rules. NHIS reimbursement listing is effectively a second regulatory gate: OVDs not listed under NHIS benefit codes face restricted uptake at public hospitals, which account for the majority of cataract surgical volume.

South Korea's Ophthalmic Viscoelastic Devices Supply Chain Outlook to 2032

Through 2032, South Korea's position as a net importer of OVDs will persist, but the import composition will shift meaningfully toward premium and combination products. The projected growth in FLACS and MICS surgical techniques across South Korea's expanding network of specialty eye hospitals — including the rapid expansion of BGN Eye Hospital and Nune Eye Hospital chains — will sustain above-market demand for high-performance OVDs. Multinational suppliers will respond by increasing direct sales force investment and establishing Korean clinical education programs to defend formulary positions. The share of standard cohesive OVDs in total import value is expected to decline from approximately 55% in 2024 to below 40% by 2032 as average selling prices rise and surgeons migrate to technically superior formulations.

The most significant structural change in South Korea's OVD supply chain by 2032 will be the potential emergence of a domestically produced hyaluronic acid OVD formulation achieving MFDS approval and NHIS listing. Several Korean biotech firms — including Humedix, a leading HA manufacturer supplying dermal filler and ophthalmic lubricant markets — are investing in intraocular-grade HA purification processes that would satisfy OVD performance standards. If a Korean-origin OVD achieves clinical validation and reimbursement listing by 2028–2030, it will displace a portion of lower-tier import volume and alter distributor economics significantly. International manufacturers should treat this development as a competitive horizon event and accelerate their premium product entrenchment strategies in South Korean hospital accounts before domestic alternatives gain procurement committee traction.

Market Segmentation

By Product Type

• Cohesive OVDs
• Dispersive OVDs
• Combination OVDs
• Viscoadaptive OVDs

By Application

• Cataract Surgery
• Corneal Transplantation
• Glaucoma Surgery
• Vitreoretinal Surgery
• Refractive Surgery

By End User

• Public Tertiary Hospitals
• Private Specialty Eye Hospitals
• Ambulatory Surgical Centers
• Ophthalmic Clinics

By Distribution Channel

• Direct Hospital Supply
• Medical Device Distributors
• Online Procurement Platforms
• Group Purchasing Organizations

Frequently Asked Questions

Q1. What is the primary logistics route for OVD imports into South Korea? ▼

The majority of OVD shipments enter South Korea via air freight through Incheon International Airport, utilizing temperature-controlled pharmaceutical handling facilities operated by Korean Air Cargo and Asiana Cargo. Cold chain integrity is maintained under GDP guidelines, with Incheon's pharma zone offering direct customs clearance to bonded medical device warehouses.

Q2. How does NHIS reimbursement affect OVD procurement decisions at South Korean hospitals? ▼

NHIS reimbursement listing is the single most influential factor in hospital formulary decisions, as public hospitals are required to prioritize NHIS-listed products for standard cataract procedures covered under national insurance. OVDs without NHIS listing are restricted to private-pay surgical cases or premium elective procedures, significantly limiting their addressable volume in the public hospital segment.

Q3. Which South Korean trade agreements most benefit OVD importers? ▼

The KORUS FTA provides the most direct benefit, eliminating the 6.5% base tariff on US-manufactured OVDs and reducing landed cost for Alcon and Johnson & Johnson Vision products. The EU-Korea FTA has largely closed the tariff gap for European-origin devices, while RCEP benefits Japanese suppliers such as Hoya through preferential rates on intraocular medical devices.

Q4. Is South Korea developing domestic OVD manufacturing capacity? ▼

Humedix and Biovisio are the two Korean companies closest to commercial OVD production, leveraging existing pharmaceutical-grade hyaluronic acid manufacturing infrastructure. Neither had achieved full MFDS intraocular device registration for an OVD product as of 2024, but regulatory submissions are anticipated by 2026–2027 based on disclosed R&D pipeline disclosures.

Q5. What surgical volume trends are driving OVD demand growth in South Korea through 2032? ▼

Annual cataract surgery volumes in South Korea are projected to increase from approximately 700,000 procedures in 2023 to over 950,000 by 2032, driven by demographic aging and expanding NHIS coverage of premium surgical techniques. Medical tourism inflows — particularly from China and Southeast Asia — add an estimated 30,000–50,000 additional ophthalmic surgical procedures annually at private Seoul-area hospitals.